In the News

Prolong Pharmaceuticals Moves Into New Headquarters

Prolong Pharmaceuticals LLC announced the expansion of its South Plainfield, N.J., manufacturing facility. A new long-term lease on the space adjoining its current facility is adding 24,000 square feet to the existing 24,000 square feet. In addition, the company secured 12,000 square feet of new executive and administrative space...

Use of SANGUINATE in encephalopathy from severe sickle cell disease

Patients with sickle cell anemia (SCD) are at increased stroke risk. Periodic blood transfusions decrease tim-averaged mean of the maximum velocities of...

Strategic Approach Needed for International Clinical Trials

Over the past two decades, the decision process for siting overseas clinical trials has become more complex for U.S. pharmaceutical companies. Once a straightforward analysis rooted in time and money, longer-term strategic issues...

Sickle Cell Disease In Three Acts

The first act in the story of sickle cell disease, one of the oldest known genetic diseases, is not a happy one. Aside from a very small number of young patients undergoing successful bone marrow or stem cell transplants, there is no curative treatment...

Prolong’s approach: Taking on multiple diseasesCompany confident Sanguinate can be difference-maker

Attacking one disease is challenging enough, but what if you can attack a disease that produces multiple disorders? Answering that question motivates Prolong Pharmaceuticals LLC, a South Plainfield biotech company developing...

Life-saving compound developed and patented at UToledo licensed to Prolong Pharmaceuticals

A compound developed at The University of Toledo that can be used to prevent blood vessels from leaking fluid into surrounding tissue following a traumatic injury to the human body has been licensed to Prolong Pharmaceuticals for...